Columbia Laboratories Inc. (NASDAQ:CBRX), CEO Frank Condella, Jr. purchased 10,000 shares of the stock in a transaction dated Monday, May 5th. The shares were purchased at an average price of $6.65 per share, for a total transaction of $66,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 45,345 shares in the company, valued at approximately $301,544. Columbia Laboratories Inc. (NASDAQ:CBRX), net profit margin is 23.50% and weekly performance is 1.37%. On last trading day company shares ended up $6.67. Analysts mean target price for the company is $10.00. Columbia Laboratories Inc. (NASDAQ:CBRX), distance from 50-day simple moving average (SMA50) is -1.28%.
On May 13, 2014, pSivida Corp. (NASDAQ:PSDV), a leader in the development of sustained release, drug delivery products for treating eye diseases, announced financial results for its third quarter ended March 31, 2014. Net loss for the quarter ended March 31, 2014 was $2.2 million, or $0.08 per share, compared to a net loss of $2.8 million, or $0.12 per share, for the prior year quarter. The reduced net loss in the third quarter of fiscal 2014 primarily reflected the recognition of revenues in the fiscal 2014 third quarter noted above, partially offset by costs in the quarter associated with the Phase III clinical trial of Medidur for posterior uveitis, which had not commenced in last year’s third quarter. pSivida Corp. (NASDAQ:PSDV), fell1.85% in last trading session and ended the day on $3.72. PSDV, return on assets is -62.10%. pSivida Corp. (NASDAQ:PSDV), quarterly performance is -14.87%.
Equities research analysts at Maxim Group lowered their target price on shares of IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), from $9.00 to $7.00 in a research note issued to investors on Thursday, StockRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective suggests a potential upside of 72.84% from the company’s current price. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), shares moved down 0.53% in last trading session and was closed at $3..72, while trading in range of $3.70 – 3.79. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), year to date (YTD) performance is 0.27%.
Shares of Flamel Technologies S.A. (ADR) (NASDAQ:FLML), dropped 6.5% during trading on Monday following a weaker than expected earnings announcement, American Banking News reports. The company traded as low as $10.54 and last traded at $10.62, with a volume of 100,329 shares. The stock had previously closed at $11.36. Flamel Technologies S.A. (ADR) (NASDAQ:FLML), ended the last trading day at $11.53. Company weekly volatility is calculated as 5.98% and price to cash ratio as 47.43. Flamel Technologies S.A. (ADR) (NASDAQ:FLML), showed a positive weekly performance of 14.96%.
Zacks reissued their neutral rating on shares of Petmed Express Inc (NASDAQ:PETS), in a research report sent to investors on Friday morning. The firm currently has a $14.00 price target on the stock. Petmed Express Inc (NASDAQ:PETS), net profit margin is 9.70% and weekly performance is -1.48%. On last trading day company shares ended up $13.28. Analysts mean target price for the company is $14.00. Petmed Express Inc (NASDAQ:PETS), distance from 50-day simple moving average (SMA50) is 2.15%.
Leave a Reply